Hepatitis Monthly

Published by: Kowsar

Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation

Mohammad Ebrahim Ghamar Chehreh 1 , Mohsen Vahedi 2 , Mohammad Amin Pourhoseingholi 3 , Sara Ashtari 3 , * , Hossein Khedmat 1 , Mohsen Amin 1 , Mohammad Reza Zali 3 and Seyed Moayed Alavian 1
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, IR Iran
3 Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Science, Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 2013, 13 (5); e7382
  • Published Online: May 8, 2013
  • Article Type: Research Article
  • Received: August 15, 2012
  • Revised: February 18, 2013
  • Accepted: April 6, 2013
  • DOI: 10.5812/hepatmon.7382

To Cite: Ghamar Chehreh M E, Vahedi M, Pourhoseingholi M A, Ashtari S, Khedmat H, et al. Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation, Hepat Mon. 2013 ;13(5):e7382. doi: 10.5812/hepatmon.7382.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hajiaghamohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Phytother Res. 2012; 26(9): 1381-4[DOI][PubMed]
  • 2. Sohrabpour AA, Rezvan H, Amini-Kafiabad S, Dayhim MR, Merat S, Pourshams A. Prevalence of nonalcoholic steatohepatitis in Iran: a population based study. Middle East J Digest Dis. 2011; 2(1): 14-9
  • 3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5): 1202-19[DOI][PubMed]
  • 4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1): 113-21[PubMed]
  • 5. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004; 53(5): 750-5[PubMed]
  • 6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6): 1413-9[PubMed]
  • 7. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22(6): 1714-9[PubMed]
  • 8. Cortez-Pinto H, Baptista A, Camilo ME, De Moura MC. Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003; 48(10): 1909-13[PubMed]
  • 9. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989; 20(6): 594-8[PubMed]
  • 10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990; 11(1): 74-80[PubMed]
  • 11. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005; 330(6): 326-35[PubMed]
  • 12. Volzke H, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, et al. Menopausal status and hepatic steatosis in a general female population. Gut. 2007; 56(4): 594-5[DOI][PubMed]
  • 13. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4): 917-23[DOI][PubMed]
  • 14. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007; 24(1): 1-6[DOI][PubMed]
  • 15. Pagadala MR, McCullough AJ. Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol. 2012; 107(12): 1859-61[DOI][PubMed]
  • 16. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867-71[PubMed]
  • 17. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365(9468): 1415-28[DOI][PubMed]
  • 18. Medical Lows and Tariffs. The price list by Iranian cabinet of the public health centers. 2010;
  • 19. List of price of drugs. 2010;
  • 20. Trading Economic Website. 2010;
  • 21. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004; 20(6): 623-8[DOI][PubMed]
  • 22. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005; 54(3): 603-8[PubMed]
  • 23. Pourshams A, Malekzadeh R, Monavvari A, Akbari MR, Mohamadkhani A, Yarahmadi S, et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol. 2005; 20(2): 229-33[DOI][PubMed]
  • 24. Iranian Databases of Census Publication. 2010;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader